Mark Lawler

11.4k total citations · 1 hit paper
249 papers, 5.9k citations indexed

About

Mark Lawler is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Mark Lawler has authored 249 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 64 papers in Molecular Biology and 63 papers in Hematology. Recurrent topics in Mark Lawler's work include Hematopoietic Stem Cell Transplantation (32 papers), Economic and Financial Impacts of Cancer (26 papers) and Cancer Genomics and Diagnostics (23 papers). Mark Lawler is often cited by papers focused on Hematopoietic Stem Cell Transplantation (32 papers), Economic and Financial Impacts of Cancer (26 papers) and Cancer Genomics and Diagnostics (23 papers). Mark Lawler collaborates with scholars based in United Kingdom, Ireland and Italy. Mark Lawler's co-authors include Donal Hollywood, Peter Humphries, SR McCann, Shaun R. McCann, Antoinette S. Perry, Laure Marignol, Mary Coffey, Owen Smith, Sandra Van Schaeybroeck and Richard Sullivan and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Mark Lawler

239 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integrating Genomics into Healthcare: A Global Responsibility

2019 242 citations Mark Lawler et al. profile →

Peers

Countries citing papers authored by Mark Lawler

Since Specialization

Citations

This map shows the geographic impact of Mark Lawler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lawler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lawler more than expected).

Fields of papers citing papers by Mark Lawler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lawler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lawler. The network helps show where Mark Lawler may publish in the future.

Co-authorship network of co-authors of Mark Lawler

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lawler. A scholar is included among the top collaborators of Mark Lawler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lawler. Mark Lawler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Central and Eastern Europe: A crucible for clinical cancer innovation? 2025 ·Journal of Cancer Policy ·Mark Lawler, (unknown), (unknown), (unknown), (unknown), Piotr Rutkowski, (unknown), (unknown), Axel Glasmacher	0
2	Ensuring equitable and affordable access to clean water for people living with cancer in a rural and coastal setting 2025 ·Journal of Cancer Policy ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ros Kane, Peter J. Selby, Mark Lawler, David Nelson	0
3	Invisible geographies - the rural and coastal blind spot in UK cancer policy: A content analysis 2025 ·Journal of Cancer Policy ·David Nelson, Natália Calanzani, (unknown), Katie Spencer, (unknown), (unknown), Maxime Inghels, (unknown), Ros Kane, (unknown), Eila Watson, (unknown), Rebecca Foster, Lynn Calman, Peter J. Selby, Mark Lawler, Peter Murchie	0
4	Empowering effective biomarker-driven precision oncology: A call to action 2024 ·European Journal of Cancer ·Mark Lawler, (unknown), Olga Kholmanskikh, (unknown), (unknown), Nicola Normanno, Reena Philip, (unknown), (unknown), Ademi Santiago-Walker, (unknown), Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Richard J. Vart, Jessica Vermeulen, Marianna Vitaloni, Jaap Verweij	18
5	Implementing the European code of cancer practice in rural settings 2024 ·Journal of Cancer Policy ·David Nelson, Peter J. Selby, Ros Kane, (unknown), Amanda Kenny, (unknown), (unknown), Todd Hogue, Kathy Oliver, Mark Gussy, Mark Lawler	5
6	Cost consequences of unscheduled emergency admissions in cancer patients in the last year of life 2023 ·Supportive Care in Cancer ·Ethna McFerran, (unknown), (unknown), Anna Gavin, Mark Lawler	5
7	Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients 2023 ·European Journal of Cancer ·Kirsty Taylor, Jinfeng Zou, (unknown), Marc Oliva, Anna Spreafico, Aaron R. Hansen, Simon S. McDade, Vicky M. Coyle, Mark Lawler, Elena Elimova, Scott V. Bratman, Lillian L. Siu	14
8	Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional data 2022 ·Disease Models & Mechanisms ·(unknown), Raheleh Amirkhah, James G. Jackson, Tamsin R.M. Lannagan, Kathryn Gilroy, Sudhir B. Malla, Keara L. Redmond, (unknown), Simon S. McDade, Tim Maughan, Simon J. Leedham, Andrew D. Campbell, Owen J. Sansom, Mark Lawler, Philip D. Dunne	3
9	Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system 2022 ·British Journal of Cancer ·Giles Greene, Rowena Griffiths, (unknown), Ashley Akbari, Monica Jones, Jane Lyons, Ronan A Lyons, Martin Rolles, Fatemeh Torabi, (unknown), Eva Morris, Mark Lawler, Dyfed Huws	31
10	Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer 2021 ·Molecular Cancer Therapeutics ·Nyree Crawford, (unknown), Tamas Sessler, Christopher McCann, (unknown), (unknown), (unknown), (unknown), Joanne M. Munck, Tomoko Smyth, (unknown), Vanessa Martins, Mark Lawler, Philip D. Dunne, Emma Kerr, Simon S. McDade, Vicky M. Coyle, Daniel B. Longley	21
11	Synthesis, Characterization, and Biological Profiling of Ruthenium(II)-Based 4-Nitro- and 4-Amino-1,8-naphthalimide Conjugates 2020 ·Inorganic Chemistry ·Robert B. P. Elmes, (unknown), (unknown), Daniel O. Frimannsson, Jonathan A. Kitchen, Mark Lawler, D. Clive Williams, Susan J. Quinn, Thorfinnur Gunnlaugsson	20
12	ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA 2019 ·Cancer Research ·(unknown), (unknown), Kienan I. Savage, Paul G. O’Reilly, (unknown), Philip D. Dunne, Mark Lawler, Simon S. McDade, David Waugh, Darragh G. McArt	6
13	Epithelial‐to‐mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition 2018 ·The Journal of Pathology ·Amy M.B. McCorry, Maurice B. Loughrey, Daniel B. Longley, Mark Lawler, Philip D. Dunne	18
14	Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies 2018 ·The Journal of Pathology ·(unknown), Susan D. Richman, Simon Gollins, Peter Stewart, Chris Hurt, Richard Adams, Amy M.B. McCorry, (unknown), Dale Vimalachandran, Claudio Isella, Enzo Médico, Tim Maughan, Darragh G. McArt, Mark Lawler, Philip D. Dunne	40
15	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification 2017 ·Nature Communications ·Philip D. Dunne, (unknown), Paul G. O’Reilly, (unknown), Amy M.B. McCorry, Susan D. Richman, Tim Maughan, Simon S. McDade, Patrick G. Johnston, Daniel B. Longley, Elaine W. Kay, Darragh G. McArt, Mark Lawler	53
16	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy 2016 ·Cancer Immunology Research ·Philip D. Dunne, Darragh G. McArt, Paul G. O’Reilly, Helen G. Coleman, Wendy L. Allen, Maurice B. Loughrey, Sandra Van Schaeybroeck, Simon S. McDade, Manuel Salto‐Tellez, Daniel B. Longley, Mark Lawler, Patrick G. Johnston	31
17	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer 2016 ·Clinical Cancer Research ·Philip D. Dunne, Darragh G. McArt, Conor A. Bradley, Paul G. O’Reilly, Helen L. Barrett, Robert Cummins, (unknown), Ken Arthur, Maurice B. Loughrey, Wendy L. Allen, Simon S. McDade, David Waugh, Peter W. Hamilton, Daniel B. Longley, Elaine W. Kay, Patrick G. Johnston, Mark Lawler, Manuel Salto‐Tellez, Sandra Van Schaeybroeck	103
18	HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF -Mutant Colorectal Cancer by Downregulation of c-FLIPL 2015 ·Clinical Cancer Research ·(unknown), (unknown), (unknown), (unknown), Nyree Crawford, Lucía Pérez–Carbonell, Mark Lawler, Daniel B. Longley, Patrick G. Johnston, Sandra Van Schaeybroeck	55
19	The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia 2009 ·Cancer Research ·(unknown), (unknown), Lisa M. Greene, Siobhan McGuckin, (unknown), Paul Browne, Stefania Butini, Giuseppe Campiani, Mark Catherwood, Elisabeth Vandenberghe, D. Clive Williams, Daniela M. Zisterer, Mark Lawler	30
20	Investing in ICTs in educational institutions in developing countries: An evaluation of their impact in Kenya 2007 ·The International Journal of Education and Development using Information and Communication Technology (The University of the West Indies) ·(unknown), Mark Lawler	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact